Use of lck inhibitor for treatment of immunologic diseases
CA 2495350 C · Owner: Ernst, Steffen · Inventors: Ernst, Steffen; Heckel, Armin; Hauptmann, Rudolf
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to a method of treating immunologc diseases or pathological conditions involving an immunologc component using Lck inhibitors already known as kinase inhibitors for therapy in oncology optionally in , combination with one or more other drugs selected from NSAIDs steroids, DMARDs, immunsuppressive, biologic response modifiers and antinfectives pharmaceutical compositions comprising said LcK inhibitoir together with said other drugs, and the use of LcK inhibitors for the manufacture of a pharmaceutical composition for the treatment of immunologic diseases or pathological conditions involving an immunologic component.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 11, 2003 and granted May 29, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 11, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 11, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.